What is the 13F Pro Quality Score for CRBP?

13F Pro ranks Corbus Pharmaceuticals Holdings, Inc. (CRBP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRBP's current score at https://13fpro.ai/research/CRBP (free sign-up required for the full ranking).

Which hedge funds own the most CRBP stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRBP include Cormorant Asset Management,, ORBIMED ADVISORS, abrdn plc. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CRBP as soon as new 13F filings post.

Where does 13F Pro source CRBP data?

All Corbus Pharmaceuticals Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Corbus Pharmaceuticals Holdings, Inc. files with the SEC under CIK 1595097. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRBP in?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRBP research updated on 13F Pro?

CRBP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Corbus Pharmaceuticals Holdings, Inc.(CRBP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1595097 CRBP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $36.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CRBP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Corbus Pharmaceuticals Holdings, Inc. (CRBP), a Healthcare sector company. CRBP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $36.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Corbus Pharmaceuticals Holdings, Inc. reports net income of $-23.0M, free cash flow of $-25.6M. Top institutional holders of CRBP by reported 13-F value include Cormorant Asset Management,, ORBIMED ADVISORS, abrdn plc, based on the most recent SEC filings. CRBP trades on the Nasdaq exchange and files with the SEC under CIK 1595097. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Corbus Pharmaceuticals Holdings, Inc. directly from SEC EDGAR. Corbus Pharmaceuticals Holdings, Inc.'s 13F Pro composite quality score has ranged between 4 and 28 since 2021, currently 4.2 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-23.0M

Free Cash Flow

Q1 2026

$-25.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY21 $881.7KFY23 —FY24 —FY25 —

Net Income

-95.3% YoY

$-78.5MFY 2025

FY21 $-45.6MFY23 $-44.6MFY24 $-40.2MFY25 $-78.5M

Operating Income

-75.1% YoY

$-85.3MFY 2025

FY21 $-56.0MFY23 $-45.1MFY24 $-48.7MFY25 $-85.3M

EPS (Diluted)

-60.3% YoY

$-5.90FY 2025

FY21 $-11.15FY23 $-10.31FY24 $-3.68FY25 $-5.90

Total Assets

+7.9% YoY

$168.2MFY 2025

FY21 $107.7MFY23 $28.3MFY24 $155.9MFY25 $168.2M

Total Debt

—FY 2025

FY21 $24.3MFY23 $33.8MFY24 —FY25 —

Op. Cash Flow

-54.3% YoY

$-64.5MFY 2025

FY21 $-48.2MFY23 $-36.1MFY24 $-41.8MFY25 $-64.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2016
Revenue	—	—	—	$881.7K -77.6%	$3.9M +106.0%	$1.9M
Net Income	$-78.5M -95.3%	$-40.2M +9.9%	$-44.6M +2.3%	$-45.6M +59.0%	$-111.3M -456.4%	$-20.0M
Operating Income	$-85.3M -75.1%	$-48.7M -8.1%	$-45.1M +19.5%	$-56.0M +54.4%	$-122.8M -514.5%	$-20.0M
EPS (Diluted)	$-5.90 -60.3%	$-3.68 +64.3%	$-10.31 +7.5%	$-11.15	—	—
Total Assets	$168.2M +7.9%	$155.9M +451.4%	$28.3M -73.8%	$107.7M +5.3%	$102.3M +471.9%	$17.9M
Total Debt	—	—	$33.8M +39.2%	$24.3M +14.6%	$21.2M	—
Operating Cash Flow	$-64.5M -54.3%	$-41.8M -15.8%	$-36.1M +25.1%	$-48.2M +51.7%	$-99.7M	—

AI Insight: CRBP Financial Trends

Corbus is burning through equity at an accelerating pace — Q1 2026 operating cash outflow hit $26M, the worst in eight quarters.

• Operating losses deepened from $-11M in Q2 2024 to $-24M in Q1 2026, a more than doubling of quarterly burn.

• Equity declined from $150M in Q3 2024 to $92M in Q3 2025 before a partial recovery to $126M in Q1 2026, suggesting periodic capital raises masking underlying consumption.

• No revenue reported across all eight quarters — company remains entirely pre-commercial with zero top-line contribution.

⚠ Operating cash outflow spiked to $-26M in Q1 2026, the largest single-quarter drain recorded — runway erosion accelerating.

⚠ Equity at $126M in Q1 2026 must absorb ~$16–26M quarterly outflows; capital raise timing is a critical near-term inflection.

AI Insight: CRBP Ratio Trends

CRBP's return metrics have deteriorated sharply, with ROE deepening from -26.8% in Q4 2024 to -72.7% in Q1 2026, signaling accelerating cash burn.

• ROE worsened from -26.8% in Q4 2024 to -72.7% in Q1 2026, nearly tripling in magnitude over five quarters.

• ROA deteriorated from -24.4% in Q4 2024 to -63.6% in Q1 2026, indicating rapidly declining asset efficiency.

• ROIC fell from -35.4% in Q4 2024 to -77.0% in Q1 2026, with Q3 2025 data unavailable, suggesting extreme capital destruction.

⚠ ROE hit -101.3% in Q3 2025 — the worst single quarter on record — before partially recovering to -72.7% in Q1 2026.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods, limiting visibility into operating leverage and balance sheet risk.

⚠ TTM ROE of -66.9% and ROIC of -71.1% confirm the deterioration is structural, not isolated to a single quarter.

Get alerted when CRBP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Corbus Pharmaceuticals Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRBP

Cormorant Asset Management, LP
$22.0M2,344,971 sh
ORBIMED ADVISORS LLC
$16.3M1,737,287 sh
abrdn plc
$12.4M1,321,750 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.9M734,106 sh
CITADEL ADVISORS LLC
$6.8M727,060 sh
Prosight Management, LP
$6.5M697,108 sh
DIADEMA PARTNERS LP
$4.1M439,957 sh
Stonepine Capital Management, LLC
$3.6M383,462 sh
ARMISTICE CAPITAL, LLC
$3.4M364,000 sh
RENAISSANCE TECHNOLOGIES LLC
$3.3M346,998 sh

Fund	Value	Shares
Cormorant Asset Management, LP	$22.0M	2,344,971
ORBIMED ADVISORS LLC	$16.3M	1,737,287
abrdn plc	$12.4M	1,321,750
VANGUARD CAPITAL MANAGEMENT LLC	$6.9M	734,106
CITADEL ADVISORS LLC	$6.8M	727,060
Prosight Management, LP	$6.5M	697,108
DIADEMA PARTNERS LP	$4.1M	439,957
Stonepine Capital Management, LLC	$3.6M	383,462
ARMISTICE CAPITAL, LLC	$3.4M	364,000
RENAISSANCE TECHNOLOGIES LLC	$3.3M	346,998

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRBP on your watchlist

Track score changes the day Corbus Pharmaceuticals Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRBP a good stock to buy?

13F Pro's AI-powered analysis of Corbus Pharmaceuticals Holdings, Inc. (CRBP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRBP are available on the CRBP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRBP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRBP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Corbus Pharmaceuticals Holdings, Inc.'s investment landscape.